In 2019, the indication for pembrolizumab was expanded as the first‐line treatment for advanced NSCLC patients with PD‐L1 expression (Tumor Proportion Score [TPS] ≥1%) and no EGFR or ALK mutations. Here, ALK is linked to neoplasm.